SCHEDULE: FMR LLC Boosts Kymera Therapeutics Stake to 11.2%

FMR LLC and its affiliates, including Abigail P. Johnson, reported a beneficial ownership of 11.2% in Kymera Therapeutics Inc. common stock as of December 31, 2025.

Summary

• FMR LLC and its affiliates, including Abigail P. Johnson, beneficially own 8,928,574.12 shares of Kymera Therapeutics Inc. common stock.
• This ownership represents 11.2% of the total outstanding common stock of Kymera Therapeutics Inc.
• FMR LLC holds sole voting power over 8,921,331 shares and sole dispositive power over 8,928,574.12 shares.
• Abigail P. Johnson, as a control person of FMR LLC, is deemed to beneficially own the same aggregate amount of shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• Several FMR LLC subsidiaries and affiliates, including Fidelity Management & Research Company LLC, are involved in the beneficial ownership, with Fidelity Management & Research Company LLC beneficially owning 5% or greater of the outstanding shares.

Sentiment

Score: 7

Explanation: The disclosure of a substantial 11.2% beneficial ownership by FMR LLC, a major institutional investor, in Kymera Therapeutics Inc. is a positive signal, indicating strong institutional confidence in the company.

Positives

• Significant institutional investment from FMR LLC, a major asset manager, indicates confidence in Kymera Therapeutics Inc.'s prospects.
• A substantial 11.2% stake suggests a long-term investment perspective from a reputable financial institution.
• The explicit statement that the holding is for ordinary course of business, not for control, implies a stable, passive investment.

Future Outlook

NA

Industry Context

The biotech and pharmaceutical sectors often see significant institutional investment due to the high capital requirements and long development cycles of drug discovery. A substantial stake by a major asset manager like FMR LLC in Kymera Therapeutics Inc. can signal institutional confidence in the company's pipeline and long-term growth prospects, potentially attracting further investor interest in the sector.

Comparison to Industry Standards

• A beneficial ownership stake of 11.2% by a major institutional investor like FMR LLC is a significant holding, often seen as a vote of confidence in a company's strategic direction and potential, especially in the volatile biotechnology sector.
• Such a large stake by a prominent asset manager is comparable to other significant institutional holdings observed in emerging biotech firms, where early institutional backing can be crucial for stability and future funding rounds.

Stakeholder Impact

• Shareholders: The significant institutional ownership by FMR LLC may be viewed positively by other shareholders, potentially increasing investor confidence and stability in the stock.
• Management: The presence of a large, passive institutional investor can provide a degree of oversight and stability, without directly interfering with day-to-day operations.

Key Dates

Recommendation

While the significant institutional ownership by FMR LLC is a positive indicator of confidence in Kymera Therapeutics Inc., this Schedule 13G filing is purely an ownership disclosure and does not provide new operational or financial performance data. Therefore, without additional fundamental analysis or new company-specific news, a 'hold' recommendation is appropriate, acknowledging the institutional backing while awaiting further catalysts or financial updates.

Keywords

Kymera Therapeutics, FMR LLC, Abigail P. Johnson, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Schedule 13G, Biotechnology, Pharmaceuticals